Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Showing 51 to 100 of 258

TitleReference numberPublishedLast updated
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerMTG72
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodulesDG46
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Microwave ablation for primary or metastatic cancer in the lungIPG716
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)TA762
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA761
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA760
Transanal total mesorectal excision for rectal cancerIPG713
Colorectal cancerNG151
Prostate cancer: diagnosis and managementNG131
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Synergo for non-muscle-invasive bladder cancerMTG61
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Selpercatinib for treating advanced thyroid cancer with RET alterationsTA742
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancerTA721
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liverIPG691
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA673
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Minimally invasive radical hysterectomy for early stage cervical cancerIPG686

Results per page

  1. 10
  2. 25
  3. 50
  4. All